µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ R\.huOJh
;2@sn+@
ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ 3yKI2en"
7 $9fGo
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ #>v7"
<
4|$D.`Wu
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© phc1AN=[E
/
5x`TT
1. CD4 Nu_w@T\l
y2 +a2
2. T cell receptor(TCR) (j~V
Y;Ur8q
3. immunoglobulin superfamily (IgSF)
5pok%g
+uLo~GdbE
4. selectin Dz50,*}J
^z^>]Qd
5. anti-idiotypic antibody (¦ÁId) c"YK+2
Qi[D&47XO
6. major histocompatibility complex(MHC) NZTYT\7
b{I`$E<[
7. immunotolerance 1}BNG ,n
g\-3c=X
8. biological reponse modifier(BRM) Lq [wabF
q],R6GcVr
9. immune reponse gene (Ir gene) 2Y4&Sba^Y
6J
5)4^bk
10. reshaped antibody (or reconstituted antibody) u W|x)g11a
V`M,d~:Pr"
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© vQ/\BN
U959=e
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ ]-'9|N*}l
2SJh6U
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? 4:@|q:DR
0w['jh|,
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ >>bYg
8@aS9th$
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? tlERis
~|9LWp_
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) 'r n;|K
tTFoS[
V
¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ L||yQH7n
IJc#)J.2A
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? \.1b\\
Zax]i,Bx
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? G`#gV"PlC
5SL>q`t.bd
¡¡ HCIF9{o1j>
gqD^Bs'VF
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ }PIB b
A] ?O&m|
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔÀíºÍ½á¹û²â¶¨? U\8#Qvghf
x\hn;i<
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? z{3%Hq
SfobzX}~Jh
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ N^yO- xk
w52HN;Jm
ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ eAYW%a
}
o"_#\6
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ ms\/=96F
:iQ^1S`pH
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© a H|OA\<
Rf(x^J{
1. CD8 `?o1cf A
jbhJ;c :
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) "">fn(
9Oo*8wvGG
3. immunoglobulin fold(Ig fold) k *;{n8o?)
~2A$R'x b
4. cadherin (Ca-dependent cell adhesion moleculers) LJNie*
VVQ74b
5. idiotype-anti-idiotypic antibody immune network theory 1|EU5<
jdg
~!<C
6. HLA class II antigen R3{*v =ov
KB,~u*~!
7. complementarity-determining region (CDR) M*~v'L_sI
&v
auLp
8. perforin(or pore-forming protein ,PFP) ngkeJ)M0$
gKs/T'PW
9. high affinity IL-2 receptor K*_{Rs0P
zA'gb'MmW
10. artificial active immunization & GzhcW~
0(hv #C4
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© kHJDX;
LA;V}%y?
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ2iR:*}5
wHt#'`5
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 1O]5/Eu
$||ns@F+
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ G>[
NZE
Rg8m4x w
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ '!+P{
(DG@<K,6
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) M|[@znzR<
\8>
1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔÀí¡£ '&.)T2Kw
SLQ\Y%F
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? aDN6MZM
55>" R{q
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ J$
6-c'8
F_Z&-+,*3t
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ i14[3bPLk!
7]/dg*A )C
¡¡ 2Y E;m&
zz(!t eBC
i\kTm?BQZ
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ,2 zt.aqB
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ P3>..fhoW
0On?{Bw
¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ 4
[R8(U[g
18DTv6?QG
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© E^Q@9C<!d
g9yaNelDh)
1. immunoglobulin gene rearrangement 7=7!| UV
'}U_D:o.b
2. the common chain of cytokine receptor (or a cytokine receptor U}tl_5%)
BA~a?"HS
subunit shared by some cytokine receptors) :V&N\>Wo
+V)qep"
3. flow cytometry(FCM) JP{UgcaF
L*zbike
4. carrier effect Jt##rVN
!UBy%DN~k
5. positive selection of T lymphocytes in thymus ?j1_
n,d
IZv~[vi_
6. mouse TH1(Th1) and TH2(Th2) subsets -Qg
2qN2{
./5jx2V
7. perforin (pore-forming protein ,PFP) PV?]UUc'n<
1*Sr5N[=
8. ADCC(antibody-dependent cell-mediated cytotoxicity) 1a<]$tZk
}X=87ud
9. SH-2(src-homology region 2) M6J/mOVx5
,5/V@;i
10. Ab2¦Â (internal image) i\(\MzW*'
D,MyI#
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© *i`v~>
OQ6sv/
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? O~.U:45t
6G'<[gL
j
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? 9u?(^(.
,!`SY)
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦ÓᣠN;<//,
!/947Rn
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ *9J1$Wa
,E&Bn8L~O
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠh}avX*Lx_
+O'vj
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) ):krJ+-/y
S."7+g7Ar
ÃâÒßѧרҵ£º gA_krK,Z
&Cq{
_M
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ uyFn}y62
m=QCG)s
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? :7\9xH
;W0]66&
´«È¾²¡Ñ§×¨Òµ£º MHo1 lrZa+
R uLvG+
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ .j
U Z
QsOhz
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ L~dC(J)@ZI
vBNZ<
L\|a
Ïû»¯×¨Òµ£º 1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹ÔÑо¿µÄ½øÕ¹¡£ v)):$s?WB
Ziz=]D_
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? Wr>(#*r7q
h>wcT VF
ID4~Gn
,- '4L9
:
,p||_G&
'L{p,
cXN _*%
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ 5h8o4
iq6a|XGi
ÃâÒßѧÊÔÌâ (
R'+jWH
>|3a
9S
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© \dq!q=b\
n|i"S`
1. Fas(CD95)/FasL Ftv8@l
8~ #M{}
2. common chain of cytokine receptor
g:<?
59*M"1['Q
3 . TCR/CD3 complex +l?; )
T&xt`|
4. negaive selection of thymocytes Y
?'tUV
YQgNv` l}
5. artificial active immune z^W$%G
)%Ru#}1X6
6. anti-idiotypic h qmSE'8
<7n]Ai@Y
7. IgSF +.Bmkim
0^~\COa
8. Integrin $h28(K%
op7FZHs
9. chemokine sR=/%pVN
;(6P6@+o
10. B7/CD28 N[U9d}Zv
M>l^%`
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© fgF;&(b
o6}n8U}bk
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԲÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹ÔµÄ¹ý³Ì¡£ o-eKAkh
.ve *Vp
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ z4M1D9iPY
{CUk1+
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô»òÖ×ÁöÏà¹Ø¿¹Ô,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ <I=$ry6 8
Bw<rp-
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô¡£
%_gho
p!W[X%`)
KN[d!}
W:
$=aI"(3&
?IYY'fS"
G '#41>q+
l]#
!+@
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ 8 i0
\7Cg,Xn
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 5lmO:G1
cT'w=
1. B7/CD28 `
2%6V)s
;b%{ilx:
2. Th1 subset xtfRrX^
=@r--E
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© 8X7{vN_3K
$H2GbZ-I
4. antibody affinity maturation KL3<Iz]
\0*l,i1&
5. AP-1 x:z0EYL
79Bg]~}Z
6. single chain variable fragment£¨ScFv£© {aDFK;qG.
45+{nN[
7. NK cell receptor J !#Zi#8sF
<Gb
%uny
8. Zinkernagel-Doherty phenomenon >1|g5
Vb4;-?s_
9. Ig fold ;+_8&wbqW
^^?q$1k6r*
10. CD40/CD40L Dgi~rr1`'s
j
F5Blc
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© zICI_*~
1Ix3i9
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ Fvl`2W94;
n9UKcN-
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ s3 QEi^~
trYTs,KV
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ _"N\b%CkO
P%>?[9!Nt
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ 0!#;j{JQ
.{so
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ >P(`MSc
y\PxR708
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ n Wgv~{,x
HD-Erop
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ GESXc$E8
q)I|2~Q c^
ARB7>"
L*
|1/
{NQoS"
v5$s#f<
Yp5L+~J[
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ kX;$}7n
RU_L<Lpi
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© b|?;h21rG
s>[{}7ca
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© /1.rz{wpb
.W.;~`EW
1.Co-stimulators (or co-stimulating molecules) O|z%DkH[
d-$_|G+
2.NK-kB ~j&?/{7I
3H8Al
3.Immunoglobulin superfamily tOg=zXm
gGfq6{9g
4.antigen-presenting cell (APC) J$[Q?8
ka
jnBC;I[:
5.death domain nNR:cGfG
Ay$
>(;
6.CCR and CXCR 04JT@s"o
!J^tg2M8:
7.Lectin (or mitogen) 7),*3c ')
y
T:!%\F9
8.Clusters of differentiation, CD) *m&&1W_
!~JWYY
9.B7 family MSY N1
%b<%w
10.Cytotoxic T lymphocyte, CTL) t9D
S]Li
k3yxx]Rk/
11.IL-15 and IL-15 receptor (IL-15R) Q
p+lJAY
0/Q5d,'Y[2
12.MHC restriction JtmQzr0>
_85E=
13.Affinity-chromatography (Y;'[.
B;c=eMw
14.Cyctosprin A, CsA Sip_
~]hM
c Vg$dt
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) a71}y;W
Q9q9<J7j$
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© k4mTZ}6E
/MxCvEE
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 Dauo(Uhuo
05 g?jV
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ 9/H^t*5t
P.1Qc)m4
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹ÔµÄÌØµã¡£ +1f{_v
L]NYYP-
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© 0k7"H]J
Xr)g
ÃâÒßѧרҵ£º '%$-]~
ugRV5bUk
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ -%N}A3m!5
MIJ%_=sm4:
Ïû»¯ÄÚ¿Æ£º 5I_hh?N4Z
*IVD/9/
2.Ö×Áö¿¹Ô·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ @Zh8 QI+
81cv:|"
ѪҺ²¡Ñ§×¨Òµ£º eb(m8vLR
{<~s&EPd
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔÒò£¨Ìõ¼þ£©ÊÇʲô£¿ w7Pe
Mj,2\ijNM
n9w j[t1/
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ yqC+P
Q=MCMe
(רҵ»ù´¡: ÃâÒßѧ) h^Arb=I
mp muziH
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) 1h&)I%`?
lxr@[VQ
1. ADCC(antibody dependent cell-mediated cytotoxicity) k_-vT
d
eHY8x5uI
2. »·æß¾úËØ(cyclosporin) F9ZOSL
8Q
t=A E7
3. KIR(killer cell inhibitory receptor) 5Q2T
T $P
aEV|>K=6Y'
4. HLDA(human leucocyte differentiation antigen) bEEJV F0
(mu{~@Hw
5. Interleukin 18(IL-18) 4UkP:Vz:
Y*h`),
6. ÕûºÏËØ(integrin) ,S7~=S
6C@0[Q\ER
7. Fas/FasL @#G6z`,
(UbR%A|v;
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) ./aZV
UEx(~>
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) L|dab{9
Q#d+IIR0gK
10. Th1/Th2 z|oA{VxW>
q(w1VcLZ
11. »ùÒòÒßÃç(DNAÒßÃç) Bh.6:9{
n57c^/A*
12. chemokines and chemokine receptor 6c;?`C
TZ`]#^kU
13. ÃâÒßÄÍÊÜ o} bj!h]N
X(0:zb,#G*
14. ¹²´Ì¼¤·Ö×Ó b ?=
D7n&9Z
15. ËÀÍö½á¹¹Óò(death domain) ijR*5#5h
?U2g8D nFY
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) Kuzy&NI^w
fmT3Af
l5c
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? d}^:E
P(W\aLp
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠ-*-zU#2|
da7x 1n$D
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î h&^/, G
IhFw {=2*
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ c^q O@%s
rg]A_(3Bb
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå V~%WK
Q
N]P*6sf-6
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ EJSgTtp2
tMs|UC
3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£